Depo-Provera and Meningioma: A Plain-English July 2026 MDL Update

Bymasstortameric

Depo-Provera and Meningioma: A Plain-English July 2026 MDL Update

Here is the clean July update for people who used Depo-Provera and later
learned they had a meningioma.

This is not a quiet, early-stage filing group anymore. The Judicial Panel
on Multidistrict Litigation's July 1, 2026 pending-MDL report lists 5,830
pending actions in MDL 3140, the Depo-Provera products-liability
litigation. The cases are centralized in the Northern District of Florida
before Judge M. Casey Rodgers.

That number does not prove any one person's case. It does not create an
automatic settlement. But it does tell us something practical: the federal
court is now handling common questions about warnings, scientific proof,
expert testimony, and trial preparation in one coordinated place.

For families, the more useful question is usually this one: if a doctor
said "meningioma" after years of birth-control shots, what should be
saved, checked, and reviewed now?

What these lawsuits are really about

Depo-Provera CI is the brand-name birth-control shot that contains
medroxyprogesterone acetate. Many patients received it every three months,
sometimes for years.

The lawsuits generally allege that repeated or long-term use increased the
risk of meningioma, a tumor that grows in the membranes around the brain
and spinal cord. They also allege that patients and doctors were not given
adequate U.S. warnings soon enough.

That is different from saying every meningioma was caused by Depo-Provera.
Meningioma cases are fact-heavy. The dates of the injections matter. So do
the tumor location, the length of use, other medical history, and what the
label said when the shots were given.

A diagnosis can also look very different from one person to the next. Some
people are monitored with imaging. Others go through brain surgery,
radiation, seizure care, vision or hearing problems, balance issues,
headaches, or long recoveries. The medical records tell the story better
than memory can.

The research people are talking about

One reason the litigation grew so quickly is a 2024 study published in The
BMJ. It used French national health data and compared women who had
intracranial surgery for meningioma with matched controls.

For injectable medroxyprogesterone acetate, the study reported an odds
ratio of 5.55, with a 95% confidence interval of 2.27 to 13.56. The authors
said the excess risk was tied to prolonged use of one year or more.

That study will not answer every legal question by itself. It is still one
of the central pieces of science being discussed because it looked at the
same active ingredient used in the shot.

The label history matters too. The FDA's openFDA label record for
Depo-Provera shows a December 2025 major change for "Warnings and
Precautions, Meningioma." The warning says cases of meningiomas have been
reported after repeated administration of medroxyprogesterone acetate,
primarily with long-term use. It also says patients should be monitored for
signs and symptoms and that Depo-Provera CI should be discontinued if a
meningioma is diagnosed.

For many claimants, the key issue is what they and their prescribing
clinicians were told before that warning appeared.

Why July 2026 is an important checkpoint

MDL 3140 is now one of the larger product-liability proceedings listed in
the JPML's July 2026 actions-pending report. Current litigation updates
also report that new Depo-Provera meningioma cases were still being filed
in July.

The next stretch of the case is about proof. Daubert rulings decide what
expert opinions may be used. Bellwether preparation helps both sides see
how real juries may react to the evidence. Those steps can affect the
litigation, but they do not replace the individual review of a person's
medical and pharmacy records.

Records to gather before they disappear

If this may involve you or someone in your family, do not rely on a rough
memory of shot dates. Try to collect:

  • pharmacy records for Depo-Provera or medroxyprogesterone acetate;
  • OB-GYN, clinic, county-health, or primary-care records showing injection
    dates;
  • MRI and CT reports;
  • pathology reports, if surgery was done;
  • neurology, neurosurgery, radiation, and rehabilitation records;
  • notes about seizures, vision changes, hearing changes, headaches,
    balance problems, or missed work; and
  • insurance explanation-of-benefits records, which can help rebuild the
    timeline when clinic records are incomplete.

It is normal not to have everything. Start with two anchors: where the
shots were given and when the meningioma was first found.

Who should consider a review

A case review may make sense for someone who received Depo-Provera or
another medroxyprogesterone acetate contraceptive injection and was later
diagnosed with a meningioma. Longer use may be especially important, but
shorter use should still be looked at carefully before anyone rules it out.

Please do not stop or change any medication because of a lawsuit article.
That is a medical decision for a qualified healthcare professional who
knows your history.

The July 2026 bottom line is straightforward: the Depo-Provera meningioma
litigation is active, large, and moving through important expert and trial
steps. If your records line up with the issue in the MDL, now is the time
to preserve them and get a careful review.

Mass Tort America helps people understand whether their Depo-Provera use
and meningioma diagnosis may fit the developing litigation. This article is
attorney advertising and is for general information only. It is not medical
advice, and it is not a promise of compensation or any specific result.

Sources checked for this update include the JPML July 1, 2026 pending-MDL
reports, the FDA openFDA Depo-Provera label record, the 2024 BMJ study on
progestogens and intracranial meningioma, and current litigation coverage
from Lawsuit Information Center.

Similar Posts